文献速递淋巴瘤造血干细胞移植与细胞治疗

GLA/DRST对德国大B细胞淋巴瘤CAR-T细胞治疗的真实世界结局分析

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
PubMed 文献 · Blood · 2022-01-01

该研究基于德国干细胞移植登记处(DRST)数据,纳入2018年11月至2021年4月在21家德国中心接受axicabtagene ciloleucel(axi-cel,n=173)或tisagenlecleucel(tisa-cel,n=183)治疗的356例复发/难治性大B细胞淋巴瘤患者,中位随访11个月,12个月总生存率52%、无进展生存率30%、非复发死亡率6%;多因素分析显示桥接失败、乳酸脱氢酶升高、年龄和tisa-cel使用是无进展生存的显著危险因素。

要点

  • 12个月总生存率52%、无进展生存率30%、非复发死亡率6%,中位随访11个月
  • 非复发死亡主要由长期中性粒细胞减少和/或严重神经毒性后的感染驱动,且axi-cel组显著更高
  • 多因素分析中无进展生存的显著危险因素包括桥接失败、乳酸脱氢酶升高、年龄和tisa-cel使用

核心结论

  • 研究提示真实世界中CD19 CAR-T治疗大B细胞淋巴瘤的重要结局决定因素为桥接成功、CAR-T产品选择、乳酸脱氢酶以及无长期中性粒细胞减少和/或严重神经毒性。
  • 这些发现可能对设计风险适配的CAR-T细胞治疗策略有启示。

研究设计与样本

  • 基于德国干细胞移植登记处(DRST)的真实世界数据,纳入2018年11月至2021年4月在21家德国中心接受SOC axi-cel或tisa-cel治疗的356例大B细胞淋巴瘤患者(axi-cel n=173,tisa-cel n=183)。
  • 分析的主要结局为毒性、缓解、总生存和无进展生存。

主要发现

  • 中位随访11个月,给药后12个月总生存率52%、无进展生存率30%、非复发死亡率6%。
  • 非复发死亡主要由长期中性粒细胞减少和/或严重神经毒性后的感染驱动,且axi-cel组显著更高。
  • 多因素分析中无进展生存的显著危险因素包括桥接失败、乳酸脱氢酶升高、年龄和tisa-cel使用。
  • axi-cel与tisa-cel队列在年龄、性别、乳酸脱氢酶、国际预后指数和预处理方面可比,但tisa-cel组体能状态差、不符合ZUMA-1入组条件及需要桥接的患者显著更多。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR T-cell therapies with the aim to explore risk factors associated with outcomes. Patients who received SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for LBCL and were registered with the German Registry for Stem Cell Transplantation (DRST) were eligible. The main outcomes analyzed were toxicities, response, overall survival (OS), and progression-free survival (PFS). We report 356 patients who received axi-cel (n = 173) or tisa-cel (n = 183) between November 2018 and April 2021 at 21 German centers. Whereas the axi-cel and tisa-cel cohorts were comparable for age, sex, lactate dehydrogenase (LDH), international prognostic index (IPI), and pretreatment, the tisa-cel group comprised significantly more patients with poor performance status, ineligibility for ZUMA-1, and the need for bridging, respectively. With a median follow-up of 11 months, Kaplan-Meier estimates of OS, PFS, and nonrelapse mortality (NRM) 12 months after dosing were 52%, 30%, and 6%, respectively. While NRM was largely driven by infections subsequent to prolonged neutropenia and/or severe neurotoxicity and significantly higher with axi-cel, significant risk factors for PFS on the multivariate analysis included bridging failure, elevated LDH, age, and tisa-cel use. In conclusion, this study suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting are bridging success, CAR-T product selection, LDH, and the absence of prolonged neutropenia and/or severe neurotoxicity. These findings may have implications for designing risk-adapted CAR T-cell therapy strategies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bethge WA, Martus P, Schmitt M, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022. PMID: 35316325. doi:10.1182/blood.2021015209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。